/Investor DB

Delin Ventures — 2022 Investments

4 investments dated 2022 · listed companies and verified rows first · show all

IMMvention Therapeuticsimmventionthera.cominDec 2022✓ verified

Immvention Therapeutics develops first-in-class BACH1 inhibitors intended as an oral therapy for patients with sickle cell disease and other conditions.

BiotechDigital HealthChapel Hill, US

Jenny Ting(Director and Co-founder)Matthew Cohen(Director)Lev Osherovich(Director)Mark Vellaca(Director)Anil Goyal(CEO and Director)

BoardBenjamin Scruggs(Director)

Co-investorsHatteras Venture PartnersOUP (Osage University Partners)

Orioriliving.comin𝕏Jan 2022 · $100M

Ori develops expandable-unit technology for multifamily real estate, enabling hotel-to-housing conversions and ground-up developments that increase unit density while maintaining livability.

Construction TechHardwareImpact & Social GoodPropTech

Hasier Larrea(Founder)

Co-investorsIngka InvestmentsPresidio VenturesThe E14 FundAmadeus Capital PartnersEpisode1Khosla Ventures+4 more

Oriori.ioJan 2022 · $100M

ORI provides an integrated business planning platform for supply chain professionals, combining demand planning, S&OP, S&OE, data analytics, and long-term planning in one tool.

AI & Machine LearningLogistics & Supply ChainSaaS

Brant Slade(Founder)in

Co-investorsKickstartAmadeus Capital PartnersKhosla VenturesNorthpond VenturesNovalis LifeSciencesOctopus Ventures+2 more

Ori Biotechoribiotech.comin𝕏Jan 2022 · $100M

Ori Biotech develops manufacturing automation platforms for cell and gene therapies, addressing scalability and cost barriers that limit patient access to these treatments.

Advanced ManufacturingBiotechDeep TechHardwareHealthtechMedical Devices

Co-investorsAmadeus Capital PartnersKindred CapitalNovalis LifeSciencesOctopus VenturesNorthpond VenturesPuhua Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.